Minocycline Treatment in Retinitis Pigmentosa

Status Completed

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).

Clinical Trial Description

Retinitis Pigmentosa (RP)is a sort of inherited blinding disorders and no effective or safe treatment are widely applied for it. The worldwide prevalence of RP is estimated to be 1/5000. RP is characterized by degeneration of peripheral rod photoreceptor(PR) and associated retinal pigment epithelium(RPE) cells. Nyctalopia and visual field constriction are common symptoms. Cone degeneration and associated loss of central vision are typically followed later. Minocycline, a secord-generation, semi-synthetic tetracycline antibiotic, is a highly lipophilic molecule and can easily pass through the blood-brain barrier. Several animal experiments and clinical trials have reported that minocycline exert anti-apoptotic, anti-inflammatory and antioxidant effects in treating neurodegenerative diseases. We propose to test the effect and safety of oral minocycline for retinitis pigmentosa. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04068207
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 2
Start date	August 25, 2019
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01432847` - Cell Collection to Study Eye Diseases
Completed	`NCT04983914` - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting	`NCT03845218` - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed	`NCT00231010` - Molecular Genetics of Retinal Degenerations
Active, not recruiting	`NCT04611503` - PDE6A Gene Therapy for Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Recruiting	`NCT01914913` - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT01949623` - Biomarkers In Retinitis Pigmentosa (BIRP)	N/A
Completed	`NCT01835002` - Transcorneal Electrical Stimulation - Multicenter Safety Study	N/A
Completed	`NCT00407602` - Argus® II Retinal Stimulation System Feasibility Protocol	N/A
Completed	`NCT00515814` - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors	N/A
Completed	`NCT00100230` - DHA and X-Linked Retinitis Pigmentosa	Phase 2
Active, not recruiting	`NCT00378742` - Repository for Inherited Eye Diseases
Terminated	`NCT05085964` - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa	Phase 2
Recruiting	`NCT05805007` - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa	Early Phase 1
Recruiting	`NCT06291935` - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene	Phase 1
Recruiting	`NCT05909488` - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II	Phase 2/Phase 3
Recruiting	`NCT03078309` - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients	Early Phase 1
Completed	`NCT04238858` - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa	N/A
Active, not recruiting	`NCT01680510` - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil	Phase 1/Phase 2